Related Experiment Video
Updated: May 11, 2026
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Non-Markovian Population Dynamics: Does it Help to Optimize the Chemotherapeutic Strategy?
Dmitry A Kuznetsov1, Sergey A Roumiantsev, Majid Fallahi
1N.N.Semenov Institute for Chemical Physics, Russian Academy of Sciences, Kosygin St.4, Moscow, Russia; ; Department of Medicinal Nanobiotechnologies, N.I.Pirogov Russian State Medical University, Ostrovityanov St.1, Moscow, Russia;
International Journal of Biomedical Science : IJBS
|May 16, 2013
Summary
This study introduces a non-Markovian model to simulate anti-cancer drug distribution, optimizing chemotherapy by enhancing drug-tumor selectivity. The model accurately predicts Porphylleren-MC16 pharmacokinetics, showing potential for improved cancer treatment strategies.
Area of Science:
- Pharmacology
- Mathematical Biology
- Oncology
Background:
- Optimizing chemotherapy requires understanding drug distribution between malignant and normal cells.
- Existing models may not fully capture cell lifespan and proliferation rate differences.
- Developing targeted drug delivery systems is crucial for cancer treatment.
Observation:
- A novel non-Markovian theory of population dynamics was developed.
- The model simulates anti-cancer drug distribution considering cell lifespan and proliferation rates.
- Experimental data for Porphylleren-MC16 (PMC16) pharmacokinetics were used for pre-test validation.
Findings:
- The non-Markovian model accurately simulates drug distribution between cancer and normal cells.
- The simulation approach demonstrated potential for optimizing chemotherapeutic strategies.
- The model successfully predicted Porphylleren-MC16 pharmacokinetics, including allometric plots.
Implications:
- This simulation approach may lead to more effective and selective chemotherapy regimens.
- It offers a promising tool for optimizing drug-tumor selectivity in cancer therapy.
- The findings support the development of novel nanoparticles like PMC16 for cancer treatment.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...